ADSTILADRIN
000423
Phase 3 small_molecule active
Quick answer
ADSTILADRIN for Intermediate risk, non-muscle invasive bladder cancer is a Phase 3 program (small_molecule) at Ferring Pharmaceuticals A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ferring Pharmaceuticals A/S
- Indication
- Intermediate risk, non-muscle invasive bladder cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active